Cannabis is the illicit drug most widely available and used worldwide [1], [2], consumed by between 125 and 203 million people, largely younger age group (15–34 years), which corresponds to an annual prevalence rate of 2.8%–4.5% [1], [2]. Despite the fact that many individuals tend to discontinue cannabis use after their initial experimentation with the drug [1] and the percentage of individuals who develop dependence is lower than that associated with alcohol (15%) or tobacco (32%) use, around 9% of cannabis users develop dependence in the long term [3], [4]. Cannabis use has been associated with a range of acute and chronic mental health problems, such as anxiety, depression, neurocognitive alterations and deficits as well as increased risk of psychotic symptoms and disorders, the severity of these effects being dependent on frequency of use, age of onset and genetic vulnerability [5]–[15]. These effects are probably related to effects on the endocannabinoid system, which can modulate the neuronal activity of other neurotransmitter systems, such as dopamine, through its action on the most abundant cannabinoid receptor in brain, the cannabinoid receptor 1
